These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 35174556)

  • 1. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
    Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
    Strober B; Armstrong A; Rubant S; Patel M; Wu T; Photowala H; Crowley J
    J Dermatolog Treat; 2022 Nov; 33(7):2991-2996. PubMed ID: 35839335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
    Papp KA; Lebwohl MG; Puig L; Ohtsuki M; Beissert S; Zeng J; Rubant S; Sinvhal R; Zhao Y; Soliman AM; Alperovich G; Leonardi C
    Br J Dermatol; 2021 Dec; 185(6):1135-1145. PubMed ID: 34157132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
    Papp KA; Blauvelt A; Puig L; Ohtsuki M; Beissert S; Gooderham M; Amin AZ; Liu J; Wu T; Azam T; Stakias V; Espaillat R; Sinvhal R; Soliman AM; Pang Y; Chen MM; Lebwohl MG
    J Am Acad Dermatol; 2023 Dec; 89(6):1149-1158. PubMed ID: 37553030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
    Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
    Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
    Strober B; Bachelez H; Crowley J; Elewski BE; Gooderham M; Menter A; Strohal R; Chen MM; Wu T; Zhan T; Photowala H; Armstrong A
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):864-872. PubMed ID: 38179809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 16. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.
    Papp KA; Soliman AM; Done N; Carley C; Lemus Wirtz E; Puig L
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1291-1304. PubMed ID: 34019229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
    Lebwohl M; Soliman AM; Yang H; Wang J; Freimark J; Puig L
    J Dermatolog Treat; 2022 Jun; 33(4):2094-2101. PubMed ID: 33899655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
    Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
    [No Abstract]   [Full Text] [Related]  

  • 19. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.